AnteoTech Ltd (AU:ADO)
ASX:ADO
Top Page
AnteoTech Ltd
(Sydney:ADO)
Select Model
Select Model
Rating:40Underperform
Price Target:
AU$0.01
â–¼(-50.00% Downside)
Action:ReiteratedDate:02/28/26
The score is driven primarily by weak financial performance (persistent losses, extreme revenue volatility, and negative operating/free cash flow). Technicals are also pressured with the price below key longer-term moving averages and a negative MACD, while valuation signals are constrained by a negative P/E and no stated dividend yield.
Positive Factors
Proprietary technology
Owning proprietary coating and binding technologies creates a durable technical moat across diagnostics and battery applications. This supports product differentiation, negotiating leverage in commercial agreements, and multiple commercialization routes (product sales, partnerships, licensing) over the next months.
Negative Factors
Severe revenue volatility
Extreme revenue swings reflect inconsistent demand, lumpy contract timing, or failed commercial scale-up. Such volatility undermines forecasting, hinders multi-period planning for manufacturing and sales, and raises the risk that near-term commercialisation efforts will not deliver stable recurring revenues.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary technology
Owning proprietary coating and binding technologies creates a durable technical moat across diagnostics and battery applications. This supports product differentiation, negotiating leverage in commercial agreements, and multiple commercialization routes (product sales, partnerships, licensing) over the next months.
Read all positive factors
AnteoTech Ltd (ADO) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$35.68M
Dividend YieldN/A
Average Volume (3M)1.47M
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue Growth110.44%
EPS Growth35.90%
CountryAU
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding2,973,138,700
10 Day Avg. Volume1,501,441
30 Day Avg. Volume1,471,917
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)10.79
Price to Sales (P/S)35.07
P/FCF Ratio-5.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AnteoTech Ltd Business Overview & Revenue Model
Company Description
AnteoTech Limited, a surface chemistry company, develops, commercializes, manufactures, and distributes products for the life sciences, diagnostics, energy, and medical device markets primarily in Australia. Its products include AnteoBind ready-to...
How the Company Makes Money
AnteoTech makes money by commercialising its proprietary materials and surface-functionalisation technologies through product sales and commercial agreements with industry partners. Revenue is generated primarily from (1) sales of diagnostic-relat...
AnteoTech Ltd Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
40
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -995.80K | 968.88K | 460.40K | 365.72K | 760.88K | 898.07K |
| Gross Profit | -1.55M | 968.88K | 460.40K | 365.72K | 760.88K | 898.07K |
| EBITDA | -5.66M | -7.96M | -11.57M | -12.35M | -12.07M | -7.18M |
| Net Income | -3.69M | -6.76M | -8.88M | -12.65M | -10.72M | -6.22M |
Balance Sheet | ||||||
| Total Assets | 4.85M | 6.45M | 9.38M | 5.36M | 15.26M | 23.68M |
| Cash, Cash Equivalents and Short-Term Investments | 1.44M | 2.34M | 5.03M | 2.72M | 10.10M | 21.39M |
| Total Debt | 2.85M | 1.96M | 2.31M | 1.31M | 1.03M | 1.28M |
| Total Liabilities | 2.82M | 3.30M | 4.08M | 2.99M | 2.91M | 2.56M |
| Stockholders Equity | 2.03M | 3.15M | 5.31M | 2.38M | 12.36M | 21.11M |
Cash Flow | ||||||
| Free Cash Flow | -2.90M | -6.05M | -7.58M | -8.77M | -11.77M | -4.76M |
| Operating Cash Flow | -2.82M | -5.83M | -6.52M | -8.08M | -8.65M | -4.55M |
| Investing Cash Flow | -118.14K | -174.87K | -1.06M | -690.83K | -3.12M | -213.07K |
| Financing Cash Flow | -704.07K | 3.32M | 9.89M | 1.39M | 482.29K | 22.94M |
AnteoTech Ltd Technical Analysis
Negative
0.02
Price Trends
0.01
Negative
0.02
Negative
0.02
Negative
Market Momentum
>-0.01
Negative
<0.01
Positive
-66.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ADO, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at <0.01 is Positive, neither overbought nor oversold. The STOCH value of -66.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ADO.
AnteoTech Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$70.05M | -7.57 | -179.37% | ― | ― | 16.61% | |
53 Neutral | AU$34.90M | -6.66 | -370.40% | ― | 306.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$216.78M | 27.58 | -15.96% | ― | -40.74% | -21.21% | |
42 Neutral | AU$58.88M | -5.28 | -62.49% | ― | ― | 10.78% | |
41 Neutral | AU$37.17M | -4.45 | -93.66% | ― | 7.65% | -19.13% | |
40 Underperform | AU$35.68M | -10.60 | -142.30% | ― | 110.44% | 35.90% |
* Healthcare Sector Average
AU:ADO
AnteoTech Ltd
0.01
<0.01
20.00%
AU:CYP
Cynata Therapeutics Limited
0.30
0.11
59.46%
AU:PTX
Prescient Therapeutics Limited
0.06
0.01
33.33%
AU:SPL
Starpharma Holdings Limited
0.52
0.42
425.51%
AU:AVE
Avecho Biotechnology Limited
0.01
0.00
0.00%
AU:PIQ
Proteomics International Laboratories Ltd.
0.23
-0.24
-52.13%
AnteoTech Ltd Corporate Events
AnteoTech outlines immunodiagnostics strategy at virtual healthcare conference
Mar 25, 2026
AnteoTech used the NWR Virtual Healthcare Conference on 26 March 2026 to provide an update on its immunodiagnostics business centered on its AnteoBind surface chemistry technology. The company positioned the presentation as a high-level business u...
AnteoTech flags high-silicon anode focus at Florida battery seminar
Mar 24, 2026
AnteoTech has used a presentation at the 43rd Florida International Battery Seminar to update stakeholders on its work to maximise high silicon anode performance, a key focus area for improving lithium-ion battery energy density. The company posit...
AnteoTech to Showcase Healthcare Strategy at NWR Virtual Conference
Mar 23, 2026
AnteoTech Ltd, an ASX-listed supplier of advanced materials to the battery and life sciences diagnostics sectors, builds on a proprietary cross-linking chemistry platform to deliver products that enhance battery performance and point-of-care test ...
AnteoTech Moves to Enter US$13bn CLIA Market With New Immunoassay Partnership
Mar 2, 2026
AnteoTech has entered an agreement with a large global life sciences company to launch an initial work program developing activated magnetic particles using its AnteoBind NXT technology for chemiluminescent immunoassays. The initiative aims to cre...
AnteoTech Issues Cautious Investor Briefing for First Half FY 2026
Mar 1, 2026
AnteoTech has released an investor briefing for the first half of FY 2026, outlining an update on its business operations, financial condition and market environment. The document emphasises that the material is an informational aid only, relies i...
AnteoTech Narrows Half-Year Loss Despite Sharp Revenue Fall on Contract Timing
Feb 25, 2026
AnteoTech Ltd has released its interim financial report for the half year ended 31 December 2025, detailing a sharp fall in reported revenue from ordinary activities alongside a narrower loss. Revenue from ordinary activities declined 85% to $97,0...
AnteoTech Corrects Cessation Date for ADOAAD Options in Updated ASX Filing
Feb 9, 2026
AnteoTech Ltd has lodged an updated Appendix 3H notification concerning the cessation of certain securities, specifically correcting an error in the previously reported cessation date for its ADOAAD options. The clarification ensures the company&#...
AnteoTech Options Lapse, Removing 11.5 Million Potential Shares
Feb 9, 2026
AnteoTech Ltd has announced the cessation of two series of options, with a total of 11,475,000 securities lapsing after the conditions attached to these instruments were not, or could no longer be, satisfied. The affected options, which were due t...
AnteoTech Issues 138 Million Unlisted Options as Part of Previously Announced Transaction
Feb 4, 2026
AnteoTech Ltd has announced the issue of 138,206,230 unlisted options with an exercise price of 3.5 cents and an expiry date of 31 January 2028. The options, which form part of a previously flagged transaction and are not intended to be quoted on ...
AnteoTech Files Cleansing Notice for Share and Option Placement
Feb 4, 2026
AnteoTech has issued 245.7 million new shares and 138.2 million listed options under its 27 January placement, with the securities released without a prospectus under section 708A and accompanied by confirmation of ongoing Corporations Act complia...
AnteoTech Boosts Cash Runway as Battery and Life Sciences Pipelines Advance
Jan 29, 2026
AnteoTech’s latest quarterly update highlights a strategic push to expand its sales pipeline and enter new markets through joint development and sales partnerships, alongside a strengthened balance sheet following a A$3.5 million capital rai...
AnteoTech Names Scott Waddell Interim CFO and Company Secretary
Jan 28, 2026
AnteoTech Limited has appointed Scott Waddell as interim chief financial officer and company secretary, effective 2 February 2026, bringing three decades of corporate finance experience across multiple resource companies to the Brisbane-based adva...
AnteoTech Plans Dual Tranche Options Issue to Bolster Capital Flexibility
Jan 27, 2026
AnteoTech Ltd has announced a proposed issue of securities via a placement, comprising a maximum of 15,356,249 new unlisted options with an exercise price of 3.5 cents and an expiry date of 31 January 2028, along with 15,356,249 options under exis...
AnteoTech Plans Major Equity and Options Issue to Bolster Capital Base
Jan 27, 2026
AnteoTech Ltd has announced a proposed placement or similar issue of up to 245,699,993 ordinary fully paid shares and 245,699,992 options, comprising 122,849,996 new unlisted options with a 3.5 cent exercise price expiring 31 January 2028 and 122,...
AnteoTech Raises A$3.5m to Fast-Track Life Sciences and Battery Tech Commercialisation
Jan 27, 2026
AnteoTech Ltd has raised A$3.5 million via a discounted share placement to institutional and professional investors, boosting its pro-forma cash balance to A$6.6 million and issuing free attaching listed and unlisted options as part of the offer. ...
AnteoTech Shares Halted Pending Announcement of Material Capital Raising
Jan 21, 2026
AnteoTech Ltd has requested and been granted a trading halt on its shares by the ASX, effective from 22 January 2026, while it prepares a market announcement regarding a material capital raising. The halt will remain in place until either the comp...
AnteoTech Advances Ultranode and Anteo Product Suite as Drone Battery Demand Surges
Jan 18, 2026
AnteoTech has reported six‑month strategic progress for its Advanced Battery Technologies unit, highlighting rising commercial traction for its Ultranode™ 95 high‑silicon anode technology in the drone and defence sectors, with tw...
AnteoTech CFO and Company Secretary Andrew Cook Resigns
Jan 8, 2026
AnteoTech Ltd has announced the resignation of Andrew Cook from his dual roles as Chief Financial Officer and Company Secretary, as he departs to pursue other business interests. The board has commenced a process to identify his successor and has ...
AnteoTech Wins Serum Institute Order as Life Sciences Pipeline Accelerates
Dec 28, 2025
AnteoTech has secured a US$185,000 AnteoBind order from the Serum Institute of India under its five-year supply agreement, with shipment set for early January 2026, while simultaneously deepening the relationship through SII’s evaluation of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.